Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Completion of Acquisition of Checkpoint Therapeutics".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma has completed the acquisition of Checkpoint Therapeutics, Inc., a US-based immunotherapy and targeted oncology company. The deal was first announced in March 2025 and has now been finalised. Through this acquisition, Sun Pharma gains UNLOXCYTTM (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC), a common skin cancer. Sun Pharma paid $4.10 per share in cash, plus a non-tradable contingent value right (CVR) per share that could pay up to an additional $0.70 in cash if certain milestones are met. This move strengthens Sun Pharma's specialty and onco-dermatology portfolio, which already accounts for over 18% of company sales.
This is a positive, growth-oriented move that adds a revenue-generating, FDA-approved oncology product to Sun Pharma's specialty portfolio. It expands the company's presence in the US onco-derm market but also adds cash outflow and integration risk. Investors may see this as a strategic boost to long-term specialty growth, though near-term stock impact is likely to be muted since the deal was already known.